ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Allergan (AGN)
08/31/201608:00:00Allergan and Adamas Announce Settlement with Amneal Related to...
08/22/201608:50:00Pfizer Adds Key Cancer Drug in $14 Billion Biotech Deal
08/22/201607:30:00Valeant Names Zoetis Executive as CFO
08/21/201622:10:00Valeant Hiring Paul Herendeen as New CFO
08/18/201608:00:00Allergan to Present at 2016 Wells Fargo Healthcare Conference
08/17/201616:50:33Statement of Changes in Beneficial Ownership (4)
08/17/201616:50:06Statement of Changes in Beneficial Ownership (4)
08/17/201616:49:41Statement of Changes in Beneficial Ownership (4)
08/11/201608:00:00Allergan to Acquire Eye Care Company ForSight VISION5 Adding...
08/09/201615:14:21Statement of Changes in Beneficial Ownership (4)
08/09/201615:05:55Statement of Changes in Beneficial Ownership (4)
08/09/201615:05:55Statement of Changes in Beneficial Ownership (4)
08/09/201615:05:27Statement of Changes in Beneficial Ownership (4)
08/09/201615:03:57Statement of Changes in Beneficial Ownership (4)
08/09/201615:03:29Statement of Changes in Beneficial Ownership (4)
08/09/201615:03:00Statement of Changes in Beneficial Ownership (4)
08/09/201615:02:35Statement of Changes in Beneficial Ownership (4)
08/09/201615:02:09Statement of Changes in Beneficial Ownership (4)
08/09/201615:01:43Statement of Changes in Beneficial Ownership (4)
08/09/201603:03:00Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles...

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations